A Phase 1 interventional study of DWJ1622 and DWC202313, DWC202314 in Healthy Volunteers, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fed conditions.
This is an open-label, randomized, oral, single-dose, 2-sequence, 2-period, crossover Phase 1 study to evaluate the pharmacokinetics and safety profiles of DWJ1622, DWC202313, and DWC202314 in healthy volunteers under fed conditions. Subjects will be randomized to receive either DWJ1622 or the co-administration of DWC202313 and DWC202314 in different sequences across two study periods with an appropriate washout period.
The primary pharmacokinetic endpoints include the maximum observed plasma concentration (Cmax) and the area under the plasma concentration-time curve to the last measurable concentration (AUClast) of each study drug. Secondary endpoints include the area under the plasma concentration-time curve extrapolated to infinity (AUCinf), the ratio of AUClast to AUCinf (AUClast/AUCinf), the time to reach maximum plasma concentration (Tmax), and the terminal elimination half-life (t1/2). Safety will be evaluated based on adverse events and clinical laboratory tests.
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: DWJ1622 · Drug: DWC202313, DWC202314
Drug: DWJ1622 · Drug: DWC202313, DWC202314
DWJ1622 (single oral dose) is administered in accordance with the study protocol.
DWC202313, DWC202314(single oral dose) is administered in accordance with the study protocol.
Cmax
Cmax of DWJ1622 and DWC202313, DWC202314
Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
AUClast
AUClast of DWJ1622 and DWC202313, DWC202314
Time frame: Time Frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
AUCinf
AUCinf of DWJ1622 and DWC202313, DWC202314
Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
AUClast/AUCinf
AUClast/AUCinf of DWJ1622 and DWC202313, DWC202314
Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
Tmax
Tmax of DWJ1622 and DWC202313, DWC202314
Time frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.
Start is estimated for Dec 2025; primary completion for Jan 2026, 1 month later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD. →